Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02187302 · ClinicalTrials.gov registry record · Phase 2

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

A Phase 2 study of Metastatic Renal Cell Carcinoma, sponsored by NewLink Genetics Corporation.

Completed
Registry status
Phase 2
Development phase
115
Enrollment target
20
Study locations

NCT02187302 is a Phase 2 study of Metastatic Renal Cell Carcinoma that has completed, run by NewLink Genetics Corporation. The registered enrollment target is 115 participants, below the 140-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (18% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02187302, a Phase 2 study of Metastatic Renal Cell Carcinoma, has completed, sponsored by NewLink Genetics Corporation.

COMPLETED
Registry status
Phase 2
Development phase
115 participants
Enrollment target
20
Study locations

Study Summary

This study to evaluate treatment in patients with metastatic renal cell carcinoma (RCC) which has progressed through 2 to 3 prior lines of therapy, with the investigational drug CRLX101 in combination with bevacizumab compared to treatment with a standard of care therapy. The study will compare which treatment resulted in longer time before progression of the RCC. Patients will be treated and followed for progression of their disease on average for up to 6 months.

Conditions Studied

Metastatic Renal Cell Carcinoma

Interventions

  • DRUG Bevacizumab
  • DRUG CRLX101
  • DRUG Standard of Care (Investigator Choice)

Study Locations (20)

California

  • University of California San Diego - La Jolla
  • David Geffen School of Medicine UCLA - Los Angeles
  • Cedars Sinai Medical Center - Los Angeles

Indiana

  • Indiana University School of Medicine - Indianapolis
  • Franciscan St. Francis Health - Indianapolis

Kansas

  • The University of Kansas Cancer Center - Fairway
  • Cancer Center of Kansas - Wichita

Michigan

  • Ann Arbor Hematoloty-Oncology - Ann Arbor
  • Karmanos Cancer Institute - Detroit

Colorado

  • Rocky Mountain Cancer Centers - Denver

Georgia

  • Emory University - Atlanta

Hawaii

  • Kaiser Permanente - Honolulu

Illinois

  • Decatur Memorial Hospital - Decatur

Trial Details

FieldValue
Enrollment Target 115 participants
Start Date 2014-07
Est. Completion 2017-01
Phase Phase 2

Sponsor

NewLink Genetics Corporation

31 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02187302

The ClinicalTrials.gov registry entry for NCT02187302 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (18% lower). The listed sponsor is NewLink Genetics Corporation, which has 31 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.

NCT02187302 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Indiana, Kansas.

Frequently Asked Questions

What is clinical trial NCT02187302 about?

NCT02187302 is a clinical study titled "CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)". This study to evaluate treatment in patients with metastatic renal cell carcinoma (RCC) which has progressed through 2 to 3 prior lines of therapy, with the investigational drug CRLX101 in combination with bevacizumab compared to treatment with a standard of care therapy. The study will compare whic...

What is the current status of trial NCT02187302?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2014-07. Estimated completion is 2017-01.

What conditions does trial NCT02187302 study?

This clinical trial studies the following conditions: Metastatic Renal Cell Carcinoma.

What interventions are being tested in trial NCT02187302?

The interventions under investigation include: Bevacizumab (DRUG), CRLX101 (DRUG), Standard of Care (Investigator Choice) (DRUG).

Who is sponsoring clinical trial NCT02187302?

This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02187302 being conducted?

This trial has 20 study locations across California, Colorado, Georgia, Hawaii, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Renal Cell Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.